PRDX1 and acute myeloid leukemia: Additionally, OXPHOS, an ATP-producing metabolic process that is highly utilized by AML CD34 + CD38− LSCs [35], was significantly more active in samples with high PRDX1 expression, highlighting PRDX1's potential role in AML pathogenesis.